BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19470935)

  • 1. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
    Zighelboim I; Schmidt AP; Gao F; Thaker PH; Powell MA; Rader JS; Gibb RK; Mutch DG; Goodfellow PJ
    J Clin Oncol; 2009 Jul; 27(19):3091-6. PubMed ID: 19470935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Zighelboim I; Ali S; Lankes HA; Backes F; Moore K; Mutch D; Robison K; Behbakht K; Waggoner S; Ghebre RG; Pearl M; Ramirez NC; Goodfellow P
    Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers.
    Lewis KA; Bakkum-Gamez J; Loewen R; French AJ; Thibodeau SN; Cliby WA
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1061-8. PubMed ID: 17879369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
    Zighelboim I; Goodfellow PJ; Gao F; Gibb RK; Powell MA; Rader JS; Mutch DG
    J Clin Oncol; 2007 May; 25(15):2042-8. PubMed ID: 17513808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
    Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
    Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    McMeekin DS; Tritchler DL; Cohn DE; Mutch DG; Lankes HA; Geller MA; Powell MA; Backes FJ; Landrum LM; Zaino R; Broaddus RD; Ramirez N; Gao F; Ali S; Darcy KM; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
    J Clin Oncol; 2016 Sep; 34(25):3062-8. PubMed ID: 27325856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance.
    Lewis KA; Mullany S; Thomas B; Chien J; Loewen R; Shridhar V; Cliby WA
    Cancer Res; 2005 Aug; 65(16):7091-5. PubMed ID: 16103057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
    Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
    Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
    Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).
    Mackay HJ; Gallinger S; Tsao MS; McLachlin CM; Tu D; Keiser K; Eisenhauer EA; Oza AM
    Eur J Cancer; 2010 May; 46(8):1365-73. PubMed ID: 20304627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer.
    Kawaguchi M; Banno K; Yanokura M; Kobayashi Y; Kishimi A; Ogawa S; Kisu I; Nomura H; Hirasawa A; Susumu N; Aoki D
    Int J Oncol; 2009 Nov; 35(5):977-82. PubMed ID: 19787250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
    An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
    Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
    Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
    Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.